99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS). Issue 1 (April 2015) - Garcia-Manero, G.; Savona, M.R.; Gore, S.D.; Cogle, C.R.; Conkling, P.; Hetzer, J.; Dong, Q.; Ukrainskyj, S.M.; Skikne, B.S.